Jan 28 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS PROVIDES ENROLLMENT UPDATE FOR ITS PHASE 3 PRESECO TRIAL EVALUATING THE ORAL ANTIVIRAL FAVIPIRAVIR AS AN EARLY TREATMENT IN COVID-19
* APPILI THERAPEUTICS INC - COMPANY IS PRIORITIZING RESOURCES ON PIVOTAL STUDY AND EXPECTS TO PROVIDE INTERIM DATA READOUT BY LATE MARCH 2021
* APPILI THERAPEUTICS - 12 SITES IN U.S. ACTIVELY RECRUITING FOR DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN MILD-TO-MODERATE PATIENTS WITH COVID-19
* APPILI THERAPEUTICS INC - PRESECO IS EVALUATING FAVIPIRAVIR, AN ORAL ANTIVIRAL, IN EARLY TREATMENT OF COVID-19 IN OUTPATIENT SETTING
* APPILI THERAPEUTICS INC - PURSUING REGULATORY APPROVALS TO EXPAND PRESECO INTO SITES IN MEXICO, BRAZIL, AND COLOMBIA